SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pharma stocks tumble after US imposes 100% tariff on branded pharmaceutical exports

26 Sep 2025 Evaluate

Indian pharmaceutical stocks declined after US President Donald Trump's move to impose 100% import tariffs on pharmaceutical drugs from October 1.

Sun Pharmaceutical Industries is currently trading at Rs. 1579.35, down by 48.65 points or 2.99% from its previous closing of Rs. 1628.00 on the BSE. The scrip opened at Rs. 1590.60 and has touched a high and low of Rs. 1602.90 and Rs. 1547.25 respectively. So far 246150 shares were traded on the counter. 

Lupin is currently trading at Rs. 1927.00, down by 34.45 points or 1.76% from its previous closing of Rs. 1961.45 on the BSE. The scrip opened at Rs. 1923.30 and has touched a high and low of Rs. 1950.65 and Rs. 1912.90 respectively. So far 20214 shares were traded on the counter.

Dr. Reddy's Laboratories is currently trading at Rs. 1255.25, down by 19.55 points or 1.53% from its previous closing of Rs. 1274.80 on the BSE. The scrip opened at Rs. 1248.10 and has touched a high and low of Rs. 1277.95 and Rs. 1245.30 respectively. So far 75324 shares were traded on the counter.

US President Donald Trump has imposed 100% tariffs on branded and patented pharmaceutical exports. The move has rattled Indian pharma stocks, even though most companies earn from US markets by selling generic drugs. On Indian pharmaceutical exports front, the US represents the primary market, comprising approximately 35% of total exports, with a value reaching about $10 billion in FY25.

Sun Pharma Inds. Share Price

1676.00 0.80 (0.05%)
20-Apr-2026 09:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1676.00
Dr. Reddys Lab 1235.40
Cipla 1235.05
Zydus Lifesciences 941.20
Lupin 2330.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×